InflaRx N.V. (IFRX)

Currency in USD
0.940
+0.030(+3.30%)
Closed·
0.932-0.008(-0.89%)
·
Unusual trading volume
IFRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.8901.003
52 wk Range
0.7111.940
Key Statistics
Prev. Close
0.91
Open
0.89
Day's Range
0.89-1.003
52 wk Range
0.711-1.94
Volume
1.03M
Average Volume (3m)
450.98K
1-Year Change
-26.5625%
Book Value / Share
0.72
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IFRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
8.880
Upside
+844.67%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

InflaRx N.V. News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.

Compare IFRX to Peers and Sector

Metrics to compare
IFRX
Peers
Sector
Relationship
P/E Ratio
−1.2x−1.3x−0.5x
PEG Ratio
−0.090.040.00
Price/Book
1.3x4.5x2.6x
Price / LTM Sales
1,878.3x7.6x3.1x
Upside (Analyst Target)
-40.5%57.5%
Fair Value Upside
Unlock12.2%8.6%Unlock

Analyst Ratings

6 Buy
2 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 8.880
(+844.67% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Raymond James
Buy7.00+644.68%-MaintainMar 20, 2026
Guggenheim
Buy14.00+1,389.36%22.00MaintainMar 20, 2026
Raymond James
Buy9.00+857.45%-MaintainDec 31, 2025
Leerink Partners
Hold2.00+112.77%-DowngradeDec 03, 2025
Guggenheim
Buy22.00+2,240.43%10.00MaintainNov 11, 2025

Earnings

Latest Release
Mar 19, 2026
EPS / Forecast
-0.15 / -0.15
Revenue / Forecast
-15K / 123.43K
EPS Revisions
Last 90 days

IFRX Income Statement

People Also Watch

2.6500
WTO
-6.03%
1.870
CRBU
-5.08%
0.422
GOSS
-6.64%
1.600
CDXS
-4.19%

FAQ

What Is the InflaRx (IFRX) Stock Price Today?

The InflaRx stock price today is 0.940 USD.

What Stock Exchange Does InflaRx Trade On?

InflaRx is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for InflaRx?

The stock symbol for InflaRx is "IFRX."

What Is the InflaRx Market Cap?

As of today, InflaRx market cap is 63.680M USD.

What Is InflaRx's Earnings Per Share (TTM)?

The InflaRx EPS (TTM) is -0.678.

When Is the Next InflaRx Earnings Date?

InflaRx will release its next earnings report on May 13, 2026.

From a Technical Analysis Perspective, Is IFRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has InflaRx Stock Split?

InflaRx has split 0 times.

How Many Employees Does InflaRx Have?

InflaRx has 74 employees.

What is the current trading status of InflaRx (IFRX)?

As of Mar 22, 2026, InflaRx (IFRX) is trading at a price of 0.940 USD, with a previous close of 0.910 USD. The stock has fluctuated within a day range of 0.890 USD to 1.003 USD, while its 52-week range spans from 0.711 USD to 1.940 USD.

What Is InflaRx (IFRX) Price Target According to Analysts?

The average 12-month price target for InflaRx is 8.880 USD, with a high estimate of 24.10042809 USD and a low estimate of 2.00624783 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +844.67% Upside potential.

What Is the IFRX Premarket Price?

IFRX's last pre-market stock price is 0.915 USD. The pre-market share volume is 4,500.000, and the stock has decreased by 0.005, or 0.550%.

What Is the IFRX After Hours Price?

IFRX's last after hours stock price is 0.932 USD, the stock has decreased by -0.008, or -0.890%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.